[Not Available].

Do novel therapies in type 2 diabetes have protective effects on cardiovascular and renal complications? A number of new antidiabetic drug classes have been introduced on the market in the last decade. Regulatory authorities have required that their safety in type 2 diabetes populations with high cardiovascular risk must be assessed. Consequently, a large number of outcome studies have been initiated, several of which have been published in recent years. Overall, this has so far shown that long-acting insulin analogues, DPP4-inhibitors, GLP1-receptor agonists and SGLT2-inhibitors are safe. In addition, a few select agents within the latter two classes have been shown to be superior to placebo with respect to cardiovascular as well as renal outcomes. This review summarizes these recent trials and discusses how the results can be interpreted. It is important to emphasize that the subjects included in these studies had/have high risk for or manifest cardiovascular disease. Therefore, the results cannot be extrapolated to all individuals with type 2 diabetes.